Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma

@article{Hersey2004PhaseIS,
  title={Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma},
  author={Peter Hersey and Scott W. Menzies and Brendon John Coventry and Tam Nguyen and Margaret L. Farrelly and Susan Collins and Debbie Hirst and Heather Johnson},
  journal={Cancer Immunology, Immunotherapy},
  year={2004},
  volume={54},
  pages={208-218}
}
Previous studies in small groups of patients suggested that immunization of melanoma patients with peptide epitopes recognized by T cells could induce regression of melanoma. This approach was tested in 36 patients with stage IV melanoma. The (MHC class I–restricted) peptides were from gp100, MART-1, tyrosinase, and MAGE-3. The gp100 and MART-1 peptides had been modified to increase their immunogenicity. In half the patients (groups 3 and 4) the peptides were given in the adjuvant Montanide-ISA… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Nanotechnology in vaccine delivery.

Advanced drug delivery reviews • 2008
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 46 references

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.

Proceedings of the National Academy of Sciences of the United States of America • 2003
View 3 Excerpts

Similar Papers

Loading similar papers…